CAW
TVTX icon

Cornerstone Advisors (Washington)’s Travere Therapeutics TVTX Stock Holding History

Cornerstone Advisors (Washington)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$4K Hold
194
– – ﹤0.01% 526
2020
Q2 		$4K Buy
194
+31
+19% +$494 ﹤0.01% 528
2020
Q1 		$2K Hold
163
– – ﹤0.01% 606
2019
Q4 		$2K Hold
163
– – ﹤0.01% 614
2019
Q3 		$2K Buy
+163
New +$2.69K ﹤0.01% 608

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Cornerstone Advisors (Washington)'s TVTX Position: Q3 2020 in Review

Cornerstone Advisors (Washington) held its Travere Therapeutics (TVTX) position steady in Q3 2020 at 194 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #526.

Cornerstone Advisors (Washington) first reported a position in TVTX in Q3 2019 and has held it in 5 quarters since. 134 funds tracked by Wall St. Rank hold TVTX as of Q3 2020.

  • Cornerstone Advisors (Washington) held 194 shares of Travere Therapeutics worth $4K as of Q3 2020.
  • Cornerstone Advisors (Washington) left its Travere Therapeutics share count unchanged in Q3 2020.
  • Travere Therapeutics made up ﹤0.01% of Cornerstone Advisors (Washington)'s portfolio in Q3 2020, its #526 holding.
  • Cornerstone Advisors (Washington) first reported a position in Travere Therapeutics in Q3 2019 and has held it in 5 quarters since.
  • 134 funds tracked by Wall St. Rank held Travere Therapeutics as of Q3 2020.

Based on Cornerstone Advisors (Washington)'s 13F filing for Q3 2020, filed 20 Oct 2020.